Bruker Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Bruker develops and sells scientific instruments and analytical and diagnostic solutions through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO and BEST. Figures below are in U.S. dollars; amounts are in millions except per-share data and percentages.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $721.7 | $685.3 | +5.3% |
| Gross profit / margin | $352.8 / 48.9% | $359.7 / 52.5% | Margin down 3.6 percentage points |
| Operating income / margin | $64.8 / 9.0% | $122.7 / 17.9% | Income down 47.2% |
| Net income attributable to Bruker | $50.9 | $76.5 | Down 33.5% |
| Diluted EPS | $0.35 | $0.52 | Down $0.17 |
| Operating cash flow | $21.8 | $87.5 | Down $65.7 |
| Free cash flow (non-GAAP) | $0.4 | $62.5 | Down $62.1 |
Revenue rose 5.3%, reflecting a 3.8% contribution from acquisitions, a 1.6% increase in organic revenue, and a 0.1% unfavorable foreign-exchange impact. Service and other revenue grew 14.0%; product revenue grew 3.5%. Gross margin pressure reflected product mix, acquisitions and unfavorable currency movements. Operating expenses rose 21.5%, including higher sales and marketing, R&D, acquisition and restructuring costs. Management also cited increased investment in R&D, particularly Project Accelerate 2.0. Non-GAAP operating income was $100.7 million, with a 14.0% margin, versus $139.4 million and 20.3% a year earlier.
Segments and revenue indicators
- BSI BioSpin: Revenue $182.8 million, up 1.4%; operating income $31.2 million versus $47.4 million.
- BSI CALID: Revenue $227.9 million, down 3.7%; operating income $41.1 million versus $57.6 million. Bruker attributed the revenue decline mainly to shipment timing and expected some shipments in Q2 2024.
- BSI NANO: Revenue $240.4 million, up 14.7%; operating income $10.8 million versus $29.4 million. Revenue growth reflected demand across key markets.
- BEST: Revenue $73.1 million, up 17.5%; operating income $8.1 million versus $8.0 million.
Remaining performance obligations were approximately $2.306 billion at March 31, 2024. Contract liabilities were $590.8 million, up from $491.4 million at year-end 2023.
Cash, liquidity and debt
Cash and cash equivalents were $340.1 million at March 31, down from $488.3 million at December 31, 2023. Total debt, including finance leases, was $1.379 billion, versus $1.282 billion at year-end; $255 million was drawn on the revolving facility at quarter-end. The company reported $644.7 million available under its $900 million revolving credit agreement and compliance with debt covenants. Management said existing cash and credit facilities should support operating and investing needs for at least the next 12 months.
Operating cash flow fell to $21.8 million, primarily reflecting lower earnings and working-capital needs, including strategic inventory, acquired-business requirements, shipment timing and tax payments. Investing cash outflow was $304.2 million, including $274.5 million for acquisitions; financing cash inflow was $151.7 million. Inventory increased to $1.061 billion from $968.3 million at year-end.
Material changes, outlook and risks
- Q1 acquisitions included Chemspeed, Spectral Instruments Imaging, Nion and other businesses, for total net consideration of $288.6 million. Chemspeed contributed $4.1 million revenue and a $0.7 million pretax loss from March 6 through quarter-end; other acquired operations were not material to Q1 results.
- After quarter-end, Bruker issued CHF 431 million of senior notes and borrowed CHF 300 million under term loan facilities. It also reported additional revolving-facility borrowings of approximately $804 million following quarter-end; the May 10 balance was approximately $805 million.
- Bruker completed the approximately $923 million ELITechGroup acquisition on April 30, 2024, and acquired substantially all relevant NanoString assets for approximately $392.6 million on May 6, 2024. The NanoString transaction includes certain assumed liabilities, including U.S. litigation related to GeoMx products. A jury had awarded plaintiffs approximately $31.6 million; post-trial motions, including a request to enhance damages, remained pending.
- The BCA restructuring plan generated Q1 charges, including severance and facility-related costs. A global restructuring program announced in April for the BioSpin and CALID segments is expected to incur a further $7.4 million of charges through the remainder of 2024. The filing provides no quantified full-year revenue or earnings guidance.
- Risks highlighted include supply-chain and component shortages, inflation and higher energy and transportation costs, geopolitical and currency volatility, commodity prices, acquisition integration and execution, and estimation uncertainty under the new U.S. self-funded employee health plan. Bruker reported no material pending legal proceedings other than routine matters, but noted potential adverse outcomes and a pending related European patent application.
- Q1 foreign-exchange gains contributed to reported results: interest and other income was positive $6.8 million versus expense of $16.1 million in Q1 2023. The 2024 figure included an unrealized gain on a forward contract associated with the anticipated ELITechGroup purchase.
Investor verification priorities
- Track whether CALID shipments deferred to Q2 occur as expected and whether organic growth improves.
- Assess recovery in gross and operating margins, given the sharp Q1 declines and higher operating costs.
- Monitor post-acquisition leverage, funding costs, integration performance and cash conversion, especially after the ELITechGroup and NanoString transactions.
- Review inventory levels, operating cash flow and free cash flow for improvement from Q1.
- Follow the NanoString litigation outcome and any resulting liability, as well as restructuring costs and execution.